BioCentury
ARTICLE | Clinical News

Cabozantinib: Phase II data

June 2, 2014 7:00 AM UTC

A single-arm, open-label, U.S. Phase II trial in 37 patients with EGFR mutation-positive NSCLC that progressed following an EGFR tyrosine kinase inhibitor (TKI) therapy showed that once-daily 40 mg oral cabozantinib plus Tarceva erlotinib led to 4 partial responses. Additionally, 20 of 23 evaluable patients had a >=30% increase in tumor doubling time. The most common grade 3 adverse event was diarrhea and 2 patients had grade 3 maculopapular rash. Grade 4 adverse events included vomiting, elevated lipase and elevated amylase. The trial was sponsored by the NCI. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...